Skip to main content
. Author manuscript; available in PMC: 2022 Oct 1.
Published in final edited form as: Lancet Oncol. 2021 Sep 13;22(10):1448–1457. doi: 10.1016/S1470-2045(21)00401-0

Table 2.

Toxicity of SABR in the 80 evaluable patients.

Adverse Event Grade 2 Grade 3 Grade 4 Grade 5
Dyspnea 0 1 (1.3%) 0 0
Pneumonitis 1 (1.3%) 0 0 0
Pulmonary fibrosis 1 (1.3%) 0 0 0